1192MO Amivantamab monotherapy and in combination with lazertinib in post-osimertinib EGFR-mutant NSCLC: Analysis from the CHRYSALIS study
N. B. Leighl, Catherine A. Shu, Anna Minchom, Enriqueta Felip, Sophie Cousin, B.C. Cho, K. Park, J-Y. Han, Michael Boyer, C.K. Lee, V. Moreno Garcia, Pascale Tomasini, Santiago Viteri, Juanjuan Xie, Jennifer A. Mertz, Eunice Artis, Robert W. Schnepp, Roland E. Knoblauch, Meena Thayu, J.M. Trigo Perez
Topics & Concepts
MedicineOsimertinibInternal medicineOncologyLung cancerEpidermal growth factor receptorCombination therapyResponse Evaluation Criteria in Solid TumorsClinical trialGastroenterologyCancerErlotinibPhases of clinical researchLung Cancer Treatments and MutationsGastric Cancer Management and OutcomesLung Cancer Research Studies